Clinical Trials Logo

Liver Neoplasms clinical trials

View clinical trials related to Liver Neoplasms.

Filter by:

NCT ID: NCT00906984 Approved for marketing - Clinical trials for Hepatocellular Carcinoma

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

TheraSphere
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this protocol is to provide TheraSphere treatment for patients with liver cancer who cannot be treated by surgery. The effect on the tumor and any side effects of TheraSphere treatment will be examined. This study will provide supervised and limited access to TheraSphere treatment at University California Irvine Medical Center. TheraSphere is a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. When Y-90 is incorporated into very tiny glass beads (TheraSphere), it can be injected to the liver through blood vessels supplying the liver. This allows a large dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue. The radiation from TheraSphere is contained within the body and becomes minimally active within 7 days after treatment due to physical decay. The glass beads remain in the body, but do not cause any health problems. TheraSphere has been approved for use in the treatment of liver cancer in the United States by the Food and Drug Administration on a limited basis.

NCT ID: NCT00903396 Terminated - Colorectal Cancer Clinical Trials

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Start date: September 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase II trial is studying the side effects of palonosetron hydrochloride and to see how well it works in preventing nausea and vomiting caused by radiation therapy in patients with primary abdominal cancer.

NCT ID: NCT00900094 Completed - Breast Cancer Clinical Trials

UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer

IRB 2000-294
Start date: June 2000
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at cancer-related protein biomarkers in the blood and tumor tissue of patients with cancer and in the blood of healthy participants.

NCT ID: NCT00899002 Withdrawn - Liver Cancer Clinical Trials

Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer

Start date: July 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in stored tumor samples from younger patients with liver cancer.

NCT ID: NCT00896467 Terminated - Breast Cancer Clinical Trials

Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy

Start date: September 2007
Phase: N/A
Study type: Observational

RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may help doctors learn more about the psychological and emotional results of being in a clinical trial. PURPOSE: This clinical trial is comparing the psychological and emotional impact of participating in a randomized clinical trial with the impact of standard treatment in patients with metastatic cancer.

NCT ID: NCT00892424 Completed - Cancer Clinical Trials

Sorafenib-RT Treatment for Liver Metastasis (SLIM)

Start date: November 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Cancers that have spread to the liver from the primary cancer location (liver metastases) that cannot be removed surgically (unresectable) can be treated with chemotherapy and/or radiation therapy. Previous research has shown that tumours often have abnormal blood vessels that may reduce the effect of radiation therapy. New drugs, known as "anti-angiogenic" drugs have been shown in animal and human studies to damage or change tumour blood vessels in ways that may make tumors more sensitive to radiation treatment. 32- 44 Patients diagnosed with unresectable liver metastasis will be invited to take part in this study. The purpose of this study is to investigate the use of a new anti-angiogenic drug called Sorafenib, in combination radiation therapy and chemotherapy. The study will test how effective the new treatment is, the side effects associated with the new treatment, and to help establish safe dosages of the study medication.

NCT ID: NCT00892255 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Microwave Ablation of Resectable Liver Tumors

Start date: April 2009
Phase:
Study type: Observational

The purpose of this protocol is to pathologically evaluate the destruction by microwave ablation of primary and metastatic liver tumors. The primary aim is to measure tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System.

NCT ID: NCT00888407 Completed - Liver Cancer Clinical Trials

Community-based Hepatitis B Interventions for Hmong Adults

Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to design an intervention to increase hepatitis B (HBV) screening among Hmong Americans.

NCT ID: NCT00885950 Completed - Clinical trials for Colorectal Liver Metastases

Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants

Start date: January 2008
Phase: N/A
Study type: Observational

The purpose of the study is to determine whether anticoagulant use (i.e. salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) is able to prevent the development of the sinusoidal obstruction syndrome secondary to oxaliplatin-based neoadjuvant chemotherapy in patients suffering from colorectal liver metastases.

NCT ID: NCT00883454 Completed - Clinical trials for Hepatocellular Carcinoma

Estimation of Functional Liver Reserve Using Cholinesterases

Start date: n/a
Phase: N/A
Study type: Observational

Estimation of functional liver reserve in patients with hepatocellular carcinoma (HCC) in cirrhosis is of paramount importance to properly select candidates for surgical resection. Together with the value of bilirubin, the presence/absence of ascites and esophageal varices, and the rate of residual liver volume, which are our current parameters to measure functional liver reserve, the investigators sought to investigate the value of preoperative cholinesterases (CHE) in predict postoperative adverse outcome after hepatic resection for HCC.